Free shipping on all orders over $ 500

Lixisenatide

Cat. No. M9190

All AbMole products are for research use only, cannot be used for human consumption.

Lixisenatide Structure
Synonym:

Lyxumia; Adlyxin; ZP10A peptide

Size Price Availability Quantity
1mg USD 120  USD120 In stock
5mg USD 240  USD240 In stock
10mg USD 380  USD380 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Lixisenatide (Lyxumia, Adlyxin, ZP10A peptide) is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is a hormone that helps normalize blood sugar levels. Lixisenatide protects Ins-1 cells (a rat-derived β-cell line) from both lipid- and cytokine-induced apoptosis. Lixisenatide also prevents lipotoxicity-induced insulin depletion in human islets and preserves insulin production, storage and pancreatic β-cell function in vitro.

In ZDF rats, a continuous subcutaneous infusion of lixisenatide 50 μg/kg/day for 12 weeks significantly decreases basal blood glucose and improves oral glucose tolerance compared with control animals. It has no hypoglycemic effect and does not change HbA1c in normoglycemic rats. Lixisenatide can maintain beta cell mass and function through stimulation of islet cell proliferation and neogenesis, and inhibition of islet cell apoptosis.

Protocol (for reference only)
Cell Experiment
Cell lines both cytokine- and FFA-treated cells
Preparation method In both cytokine- and FFA-treated cells, Lixisenatide (10 nM) significantly decreased caspase-3 activity, and decreased the amount of apoptotic cells by 50–60% (similar to the effect seen with 10 nM GLP-1 or exendin-4) .
Concentrations 10 nM
Incubation time -
Animal Experiment
Animal models
Formulation
Dosages
Administration
Chemical Information
Molecular Weight 4858.53
Formula C215H347N61O65S
CAS Number 320367-13-3
Solubility (25°C) Water 90 mg/mL
Storage -20°C, dry, sealed
References

[1] Anthony H Barnett, et al. Core Evid. Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes

[2] Ulrich Werner, et al. Regul Pept. Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes

Related GLP Receptor Products
V-0219 hydrochloride 

V-0219 hydrochloride is an orally active, positive allosteric modulator (PAM) of the glucagon-like peptide-1 receptor (GLP-1R).

GLP-1 receptor agonist 14 

GLP-1 receptor agonist 14 is a potent agonist of glucagon-like peptide-1 (GLP-1).

NM-003

NM-003 is a GLP-2R agonist that can be used in studies related to inflammatory bowel disease.

NB-1002

NB-1002 is a GLP-2R agonist that can be used in studies related to short bowel syndrome.

MOD-15014

MOD-15014 is a GLP-2R modulator that can be used in studies related to short bowel syndrome.

  Catalog
Abmole Inhibitor Catalog




Keywords: Lixisenatide, Lyxumia; Adlyxin; ZP10A peptide supplier, GLP Receptor, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.